US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application for Opdivo plus chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.